<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543244</url>
  </required_header>
  <id_info>
    <org_study_id>200709053R</org_study_id>
    <nct_id>NCT00543244</nct_id>
  </id_info>
  <brief_title>Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan</brief_title>
  <official_title>Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis C virus (HCV) infection is a global health problem, which may lead to chronic
      hepatitis, cirrhosis, hepatic decompensation and hepatocellular carcinoma (HCC). Recently,
      treatment with peginterferon alfa plus ribavirin has become the standard of care for patients
      with chronic hepatitis C. While genotype 2 patients can have higher sustained virologic
      response (SVR) rates to 80-90%, genotype 1 patients generally have low SVR rates of only
      40-50%. In contrast, genotype 1 Taiwanese patients have superior SVR rates than those in
      Western countries. Despite the overall improved response to this combination therapy, more
      than 75% of patients suffer from treatment-related adverse events and the costs remain high,
      which make individualized therapy of paramount importance to maximize treatment response and
      minimize adverse events.

      HCV viral kinetics with interferon-based therapies have been studied recently to evaluate
      patient responses. Early viral kinetics shown to have favorable SVR rates, which make shorter
      treatment duration possible. However, different viral kinetics were found through ethnicity.
      Recently, a pilot study to evaluate the viral kinetics of 6 Taiwanese patients with HCV
      infection who received peginterferon alfa plus ribavirin therapy has shown superior early
      viral kinetics to those in Caucasian patients. Based on the favorable SVR rates in treating
      Taiwanese patients with chronic hepatitis C, the investigators aimed to conduct a large
      confirmatory study to evaluate the viral kinetics and try to define the optimal treatment for
      these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis C virus (HCV) infection is a global health problem, which may lead to chronic
      hepatitis, cirrhosis, hepatic decompensation and hepatocellular carcinoma (HCC). [1,2]
      Recently, treatment with peginterferon alfa plus ribavirin has become the standard of care
      for patients with chronic hepatitis C. While genotype 2 patients can have higher sustained
      virologic response (SVR) rates to 80-90%, genotype 1 patients generally have low SVR rates of
      only 40-50%. [3-5] In contrast, genotype 1 Taiwanese patients have superior SVR rates that
      those in Western countries. [6,7] Despite the overall improved response to this combination
      therapy, more than 75% of patients suffer from treatment-related adverse events and the costs
      remain high, [8,9] which make individualized therapy of paramount importance to maximize
      treatment response and minimize adverse events.

      HCV viral kinetics with interferon-based therapies have been studied recently to evaluate
      patient responses. [10-14] Early viral kinetics shown to have favorable SVR rates, which make
      shorter treatment duration possible. [15-18] However, different viral kinetics were found
      through ethnicity. [19-23] Recently, a pilot study to evaluate the viral kinetics of 6
      Taiwanese patients with HCV infection who received peginterferon alfa plus ribavirin therapy
      has shown superior early viral kinetics to those in Caucasian patients. [24] Based on the
      favorable SVR rates in treating Taiwanese patients with chronic hepatitis C, the
      investigators aimed to conduct a large confirmatory study to evaluate the viral kinetics and
      try to define the optimal treatment for these patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <primary_completion_date type="Anticipated">October 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virologic response (SVR)</measure>
    <time_frame>1~1.5 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients with chronic hepatitis C who receive pegylated interferon plus ribavirin for 24 weeks (genotype 1 or 2) and for 48 weeks (genotype 1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alfa and ribavirin</intervention_name>
    <description>Pegylated interferon alfa-2a 180 ug/week or pegylated interferon alfa-2b 1.5 ug/kg/week Ribavrin 800-1200 mg/day (genotype 1: &lt; 75 kg 1000 mg/day, &gt;=75 kg 1200 mg/day; genotype 2: 800 mg/day)
HCV genotype: baseline (Day 0) HCV RNA (real time PCR test): baseline (Day 0), Day 1 (4,8,12 hours after pegylated interferon + ribavirin), Day 2 (24,36 hours), Day 3(48 hours), Day 4 (72 hours), Day 5 (96 hours), Week 2,4,6,8,12,16,20,24, and 28,32,36,40,44,48,72 (for genotype 1 with 48 weeks of treatment), and 48 (for genotype 1 or 2 with 24 weeks of treatment)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Pegasys plus Robatrol</other_name>
    <other_name>Peg-Intron plus Rebetol</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic hepatitis C virus infection who receive pegylated interferon plus
        ribavirin for an overall of 24-48 weeks
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment naïve

          -  Over 18 years old

          -  Anti-HCV (Abbott HCV EIA 2.0, Abbott Diagnostic, Chicago, IL) positive &gt; 6 months

          -  Detectable serum quantitative HCV-RNA (Cobas Amplicor HCV Monitor v2.0, Roche
             Molecular Systems, Pleasanton, CA) with dynamic range 600~&lt; 500,000 IU/ml

          -  Serum alanine aminotransferase levels above the upper limit of normal with 6 months of
             enrollment

          -  A liver biopsy consistent with the diagnosis of chronic hepatitis C

        Exclusion Criteria:

          -  Anemia (hemoglobin &lt; 13 gram per deciliter for men and &lt; 12 gram per deciliter for
             women)

          -  Neutropenia (neutrophil count &lt; 1,500 per cubic milliliter)

          -  Thrombocytopenia (platelet &lt; 90,000 per cubic milliliter)

          -  Co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

          -  Chronic alcohol abuse (daily consumption &gt; 20 gram per day)

          -  Decompensated liver disease (Child-Pugh class B or C)

          -  Serum creatinine level more than 1.5 times the upper limit of normal

          -  Autoimmune liver disease

          -  Neoplastic disease

          -  An organ transplant

          -  Immunosuppressive therapy

          -  Poorly controlled autoimmune diseases, pulmonary diseases, cardiac diseases,
             psychiatric diseases, neurological diseases, diabetes mellitus

          -  Evidence of drug abuse

          -  Unwilling to have contraception

          -  Unwilling to receive serial blood sampling during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia-Horng Kao, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Avidan Uriel Neumann, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chen-Hua Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jia-Horng Kao, MD, PhD</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>7307</phone_ext>
    <email>kaojh@ntu.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Avidan Uriel Neumann, PhD</last_name>
    <phone>972-3-531-7970</phone>
    <email>neumann@mail.biu.ac.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Life Sciences, Bar-Ilan University</name>
      <address>
        <city>Ramat-Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Avidan Uriel Neumann, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Yun-Lin Branch</name>
      <address>
        <city>Douliou</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shih-Jer Hsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sheng-Shun Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jia-Horng Kao, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chen-Hua Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ding-Shinn Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming-Yang Lai, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pei-Jer Chen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chun-Jen Liu, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ching-Sheng Hsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chia-Chi Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cheng-Chao Liang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ren-Ai Branch, Taipei Municipal Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chih-Lin Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Chen DS, Kuo GC, Sung JL, Lai MY, Sheu JC, Chen PJ, Yang PM, Hsu HM, Chang MH, Chen CJ, et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis. 1990 Oct;162(4):817-22.</citation>
    <PMID>2169497</PMID>
  </reference>
  <reference>
    <citation>Lai MY. Combined interferon and ribavirin therapy for chronic hepatitis C in Taiwan. Intervirology. 2006;49(1-2):91-5. Review.</citation>
    <PMID>16166795</PMID>
  </reference>
  <reference>
    <citation>Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001 Sep 22;358(9286):958-65.</citation>
    <PMID>11583749</PMID>
  </reference>
  <reference>
    <citation>Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975-82.</citation>
    <PMID>12324553</PMID>
  </reference>
  <reference>
    <citation>Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004 Mar 2;140(5):346-55.</citation>
    <PMID>14996676</PMID>
  </reference>
  <reference>
    <citation>Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ, Chang WY, Chang TT, Hsieh TY, Liu CJ, Chen DS. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat. 2005 May;12(3):283-91.</citation>
    <PMID>15850469</PMID>
  </reference>
  <reference>
    <citation>Yu ML, Dai CY, Lin ZY, Lee LP, Hou NJ, Hsieh MY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL. A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int. 2006 Feb;26(1):73-81.</citation>
    <PMID>16420512</PMID>
  </reference>
  <reference>
    <citation>Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004 Apr;39(4):1147-71. Erratum in: Hepatology. 2004 Jul;40(1):269.</citation>
    <PMID>15057920</PMID>
  </reference>
  <reference>
    <citation>Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002 Nov;36(5 Suppl 1):S237-44. Review.</citation>
    <PMID>12407599</PMID>
  </reference>
  <reference>
    <citation>Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998 Oct 2;282(5386):103-7.</citation>
    <PMID>9756471</PMID>
  </reference>
  <reference>
    <citation>Lee WM, Reddy KR, Tong MJ, Black M, van Leeuwen DJ, Hollinger FB, Mullen KD, Pimstone N, Albert D, Gardner S. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group. Hepatology. 1998 Nov;28(5):1411-5.</citation>
    <PMID>9794929</PMID>
  </reference>
  <reference>
    <citation>Orito E, Mizokami M, Suzuki K, Ohba K, Ohno T, Mori M, Hayashi K, Kato K, Iino S, Lau JY. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol. 1995 Jun;46(2):109-15.</citation>
    <PMID>7636496</PMID>
  </reference>
  <reference>
    <citation>Colombatto P, Civitano L, Oliveri F, Coco B, Ciccorossi P, Flichman D, Campa M, Bonino F, Brunetto MR. Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. Antivir Ther. 2003 Dec;8(6):519-30.</citation>
    <PMID>14760885</PMID>
  </reference>
  <reference>
    <citation>Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. 2003 Jun;37(6):1351-8.</citation>
    <PMID>12774014</PMID>
  </reference>
  <reference>
    <citation>Jessner W, Stauber R, Hackl F, Datz C, Watkins-Riedel T, Hofer H, Gangl A, Kessler H, Ferenci P. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. J Viral Hepat. 2003 Jan;10(1):37-42.</citation>
    <PMID>12558910</PMID>
  </reference>
  <reference>
    <citation>Carlsson T, Reichard O, Norkrans G, Bläckberg J, Sangfelt P, Wallmark E, Weiland O. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepat. 2005 Sep;12(5):473-80.</citation>
    <PMID>16108761</PMID>
  </reference>
  <reference>
    <citation>Ouzan D, Khiri H, Pénaranda G, Joly H, Halfon P. Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients. Comp Hepatol. 2005 Dec 21;4:9.</citation>
    <PMID>16371151</PMID>
  </reference>
  <reference>
    <citation>Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006 May;43(5):954-60. Erratum in: Hepatology. 2006 Jun;43(6):1410.</citation>
    <PMID>16628671</PMID>
  </reference>
  <reference>
    <citation>Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, Joh T. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology. 1999 Sep;30(3):787-93.</citation>
    <PMID>10462387</PMID>
  </reference>
  <reference>
    <citation>McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T, Yao R, Albrecht J. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology. 2000 Nov;119(5):1317-23.</citation>
    <PMID>11054390</PMID>
  </reference>
  <reference>
    <citation>Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology. 2003 Jun;37(6):1343-50.</citation>
    <PMID>12774013</PMID>
  </reference>
  <reference>
    <citation>Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med. 2004 Aug 1;117(3):163-8.</citation>
    <PMID>15276594</PMID>
  </reference>
  <reference>
    <citation>Yu ML, Chuang WL, Dai CY, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Tsai SL, Kuo HT. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. Transl Res. 2006 Sep;148(3):120-7.</citation>
    <PMID>16938649</PMID>
  </reference>
  <reference>
    <citation>Hsu CS, Liu CJ, Lai MY, Chen PJ, Kao JH, Chen DS. Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan. Intervirology. 2007;50(4):310-5. Epub 2007 Jul 9.</citation>
    <PMID>17622791</PMID>
  </reference>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2007</study_first_submitted>
  <study_first_submitted_qc>October 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2007</study_first_posted>
  <last_update_submitted>November 20, 2008</last_update_submitted>
  <last_update_submitted_qc>November 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2008</last_update_posted>
  <responsible_party>
    <name_title>National Taiwan University Hospital</name_title>
    <organization>National Taiwan University Hospital</organization>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Pegylated interferon</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Virokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

